纳米医学
癌症研究
黑色素瘤
姜黄素
阿霉素
伊立替康
化学
细胞凋亡
切碎
下调和上调
转录组
医学
药理学
小RNA
癌症
联合疗法
癌症治疗
药物基因组学
靶向治疗
癌细胞
类有机物
柔红霉素
内质网
分子医学
生物信息学
转移
伏立诺他
威罗菲尼
作者
Yixun Zhang,Xuehua Wang,Hongli Zhang,Xin Zhou,Huichan He,Fen Zou,Yangjia Zhuo,Zhouda Cai,Qianfeng Xu,Wenjie Xie,Jundong Lin,Muqi Chen,Wenlian Zheng,Jianwei Chen,Jinsheng Liu,Huikang Yang,Weide Zhong,Ronghua Yang
标识
DOI:10.1186/s12951-025-03941-7
摘要
Melanoma has a high incidence and mortality, and current therapies are limited. Here, we developed TCPC, an ER-targeted nanomedicine guided by omics analysis. It consists of curcumin-loaded PEG-PCL nanomicelles coated with a Tannic acid-Cu metal-polyphenol network. Guided by clinical transcriptome mining, we identified ER-stress vulnerabilities to inform material design. RNA-seq and imaging confirmed that TCPC preferentially accumulates in melanoma cells and localizes to the ER. TCPC markedly elevates CHOP expression, which triggers ER Ca²⁺ release, mitochondrial dysfunction, ROS accumulation, and apoptosis. Functionally, TCPC significantly suppresses cell viability, migration, and invasion in vitro. In melanoma xenografts, systemic TCPC treatment slows tumor growth, enhances intratumoral CHOP and Cleaved caspase-3, and induces apoptosis without systemic toxicity. Moreover, pharmacogenomic analyses revealed that CHOP upregulation correlates with increased sensitivity to several agents, and molecular docking highlighted Irinotecan and JQ1 as potential synergistic partners with TCPC. Collectively, this work demonstrates that nanomedicine guided by omics can couple organelle-specific delivery with ER-stress amplification to achieve potent antitumor efficacy. Overall, this work establishes an omics-guided materials strategy that integrates organelle-targeted delivery with ER-stress amplification for effective melanoma therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI